Year: 2020

The Atos OneCloud initiative will be supported by a €2 billion investmentParis, November 16, 2020 – Atos, a global leader in digital transformation, today launches Atos OneCloud, a unique initiative to pro-actively accelerate its clients’ migration to the Cloud through a one-stop shop offering industry specific go-to-market and organization. Atos OneCloud will allow customers to unleash the business potential of Cloud through business processes optimization and application modernization, making them more agile, more mobile, more data driven and more customer centric. Supported by a dedicated c. €2 billion investment over the next 5 years, Atos OneCloud will be delivered through highly secure and decarbonized, public, private or hybrid Cloud environments.First and foremost, Atos OneCloud aims at bringing business outcomes to customers,...

Atos OneCloud bénéficiera de 2 milliards d’euros d’investissementsParis, France, 16 novembre 2020 – Atos, leader international de la transformation digitale, lance aujourd’hui Atos OneCloud, une initiative unique pour accélérer de manière pro-active la migration de ses clients vers le Cloud à travers un guichet unique d’offres, des capacités sectorielles spécifiques de mise sur le marché et une organisation dédiée. Atos OneCloud permettra aux entreprises de bénéficier de tout le potentiel du Cloud grâce à l’optimisation de leurs processus métiers et la modernisation de leurs applications, les rendant plus agiles, plus mobiles, plus axées sur les données et plus centrées sur leurs clients. Soutenu par 2 milliards d’euros d’investissements sur 5 ans, Atos OneCloud sera fourni dans des environnements de Cloud public, privé ou hybride,...

Not to be published, distributed or circulated directly or indirectly in the United States, Australia or Japan.This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any Alstom securities in any jurisdiction.Alstom launches its share capital increase with preferential subscription rights of an amount of approximately €2 billion as part of the financing of the acquisition of Bombardier Transportation November 16, 2020Terms of the transactionSubscription ratio: 3 new shares per 10 existing sharesSubscription price: €29.50 per new share; theoretical value of the preferential subscription rights: €2.90Preferential subscription rights trading period: from November 17th to November 26th, 2020, inclusiveSubscription period: from November 19th to November 30th, 2020, inclusiveFollowing...

Ce communiqué ne peut être distribué directement ou indirectement aux États-Unis, en Australie ou au Japon.Le présent communiqué de presse est diffusé à titre d’information uniquement et ne constitue pas une offre de vente ou une sollicitation d’offre d’achat de valeurs mobilières d’Alstom dans une quelconque juridiction.Alstom lance son augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 2 milliards d’euros dans le cadre du financement de l’acquisition de Bombardier Transport 16 novembre 2020Termes de l’opérationParité : 3 actions nouvelles pour 10 actions existantesPrix de souscription : 29,50 euros par action nouvelle, valeur théorique du droit préférentiel de souscription (« DPS ») à 2,90 eurosPériode de cotation des DPS : du 17 novembre au 26 novembre 2020 inclusPériode de souscription...

 Amsterdam, 16 November 2020 — AMG Advanced Metallurgical Group N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) announces the formation of AMG Chrome US LLC (“US Chrome”).  US Chrome will manufacture chrome metal products in New Castle, PA. The US Chrome plant will be located on the premises of the former International Specialty Alloys (“ISA”), which AMG acquired from Kennametal, Inc.  US Chrome will be the only producer of chrome metal in the United States. Chrome metal is classified as a critical material by the US government.US Chrome is part of AMG Superalloys, a world-leading chrome metal producer with its principal operations in Rotherham, UK.We anticipate AMG Chrome US LLC will begin production in early 2021.About AMGAMG is a global critical materials company at the forefront of CO2 reduction trends....

 Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancyMaternal, fetal and neonatal safety comparable to placeboData supports advancement of ebopiprant to Phase 2b dose range finding             Geneva, Switzerland and Boston, MA – 16 November 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of ebopiprant in preterm labor.  Ebopiprant is a new, first in class, orally active, selective prostaglandin F2α (PGF2α), receptor antagonist designed to treat preterm labor by reducing uterine contractions and cervical maturation while avoiding the adverse...

REGULATED INFORMATIONGosselies, Belgium, 16 November 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that Catalent Pharma Solutions, Inc. (“Catalent”), has completed the acquisition of Bone Therapeutics’ manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), announced on 29 October 2020. Following completion of the transaction, SCTS’ manufacturing infrastructure and production operating teams have now become part of Catalent’s Cell & Gene Therapy division.Under the terms of the transaction, Catalent acquires Bone Therapeutics’ cell therapy manufacturing subsidiary, SCTS, for gross proceeds of €12 million. The equity purchase price, net of SCTS’s debt (€3 million), cash adjustments, and taking...

INFORMATION RÉGLEMENTÉEGosselies, Belgique, le 16 Novembre 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires innovantes répondant aux besoins médicaux non satisfaits en orthopédie et dans d’autres pathologies graves, annonce aujourd’hui que Catalent Pharma Solutions, Inc. (« Catalent ») a finalisé l’acquisition de Skeletal Cell Therapy Support SA (SCTS), la filiale de production de Bone Therapeutics, publiée le 29 octobre 2020. A la suite de cette transaction, les infrastructures de fabrication et les équipes opérationnelles de production de SCTS font désormais parties de la division Thérapie Cellulaire & Génique de Catalent.Selon les termes de cette transaction, Catalent acquiert donc la filiale de production de Bone Therapeutics,...

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategyRoche performed particularly well in Marketing Practices, Environmental and Social Reporting, Operational Eco-Efficiency, Climate Strategy, and Corporate Citizenship and Philanthropy             Basel, 16 November 2020 – For the eleventh time, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Attachment16112020_MR_ DJSI_EN